List view / Grid view
25 September 2013 | By Novo Nordisk
Recruitment for the LEADER® trial assessing cardiovascular (CV) outcomes of the once-daily GLP-1 analogue, Victoza®, completed in April 2012, resulted in a high-risk population with patient numbers exceeding the original target...
20 September 2013 | By Novo Nordisk
Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion on its recombinant factor VIII product turoctocog alfa, with the intended brand name NovoEight®...
8 August 2013 | By Novo Nordisk
Sales growth of 11% driven by Victoza®, NovoRapid® and Levemir®...
24 June 2013 | By Novo Nordisk
Key results from the global Diabetes Attitudes, Wishes and Needs 2 study (DAWN2™)...
22 June 2013 | By Novo Nordisk
Findings from a new real-world study...
31 May 2013 | By Novo Nordisk
Novo Nordisk announced the submission to the EMA of the MAA for the approval of IDegLira...
30 May 2013 | By Novo Nordisk
The World Health Assembly unanimously adopted a global action plan...
17 May 2013 | By Novo Nordisk
Novo Nordisk announced the completion of paradigm™ 2...
6 May 2013 | By Novo Nordisk
Novo Nordisk is investing an additional 380 million Danish kroner in its Kalundborg plant in Denmark...
9 April 2013 | By Novo Nordisk
The first-ever Diabetes Forum takes place in Mexico City (9th April), to address the critical diabetes challenge the country is facing...
18 March 2013 | By Novo Nordisk
Novo Nordisk announced the headline results from a 56-week, double-blind phase 3a clinical trial...
7 March 2013 | By Biosector 2
NovoPen® 5 has just been approved for launch in China...
5 March 2013 | By Novo Nordisk
Novo Nordisk launches a new project to enhance the quality and accessibility of diabetes treatment in Nigeria...
14 February 2013 | By Novo Nordisk
Novo Nordisk announced that NovoSeven® is now available...
13 February 2013 | By Novo Nordisk
Novo Nordisk announced that it has received approval of the price of Tresiba® (insulin degludec)...
